| Name | Title | Contact Details |
|---|
Handcrafted outdoor furniture with over 20 years of DEDON experience. As a manufacturer of exclusive outdoor furniture, DEDON is one of the worlds leading providers in this industry and has received numerous international design awards. The company, which was founded in 1990 by the former professional soccer player Bobby Dekeyser, revolutionized the outdoor furniture market with its groundbreaking designs within only a few years. The basis for DEDONs success is a highly durable synthetic fiber manufactured at the headquarters in the North of Germany. Developed over 20 years ago, the unique DEDON fiber still is considered "the original" in the industry; the "Made by DEDON" seal stands for the highest standards of quality and design. DEDON furniture is designed by international designers, matches German quality standards in terms of production, and is manufactured by hand in a traditional fashion by braiding artisans on the island of Cebu in the Philippines. Every piece of DEDON furniture embodies the combination of modern technology and century-old craftsmanship.
Purpose Legal is a prominent provider of legal support services, focusing on eDiscovery, document review, and legal technology solutions. Founded by attorneys over a decade ago and based in Austin, TX, the company aims to enhance the efficiency of legal services through a skilled and diverse team. Purpose Legal is recognized for its commitment to diversity, with 89% of its workforce representing various backgrounds and 63% being female. The company offers a comprehensive range of services tailored to corporate legal departments and law firms. These services include secure eDiscovery solutions, thorough document reviews, and customized legal technology solutions. Purpose Legal also provides litigation support, information governance, data breach discovery, and commercial contract review. Additionally, the company applies data science techniques to improve legal operations and decision-making. Purpose Legal is trusted by a wide array of clients, including multinational corporations and government entities, and has received several prestigious certifications, ensuring high standards of quality and security.
Hal Smith Restaurants is a restaurant management company based in Norman, Oklahoma, founded in 1992 by Hal Smith. The company operates over 80 locations across seven states, featuring a diverse range of dining options from casual to upscale. Annual sales approach $250 million, and the company emphasizes strong customer service and employee training. The company develops, manages, and franchises various restaurant concepts. Its portfolio includes full-service dining options like Charleston’s Restaurant, Red Rock Canyon Grill, and Mahogany Prime Steakhouse. It also features casual and themed concepts such as Ted’s Café Escondido, Louie’s Bar & Grill, The Garage, and Pub W. Hal Smith Restaurants has a history of franchising, having previously managed Outback Steakhouse and On The Border Mexican Cafe franchises. With a focus on community-centric locations, Hal Smith Restaurants continues to expand, including new openings like Neighborhood JA.M. in Oklahoma City planned for Spring 2025. The company is dedicated to culinary excellence and creating memorable dining experiences for a wide range of customers.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.